TrialCancer discovery2017

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Dejan Juric et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.